Eosinophilic gastroenteritis: Pathogenesis, diagnosis, and treatment / 中华医学杂志(英文版)

Eosinophilic gastroenteritis (EGE) is a gastrointestinal disorder of unclear etiology that is characterized by eosinophilic infiltration of the stomach and small intestine, and consists of mucosal, muscular, and serosal subtypes. Eosinophilic infiltration of the gastrointestinal tract is a fundamental histopathological characteristic of EGE and is driven by several T-helper type 2 (Th2)-dependent cytokines and induced by food allergy. Due to the lack of a diagnostic gold standard, EGE has a high rate of delayed diagnosis or misdiagnosis. However, several new diagnostic strategies have been developed, such as novel genetic biomarkers and imaging tests. Although dietary therapy and corticosteroids remain the common choices for EGE treatment, recent decades have seen the emergence of novel treatment alternatives, such as biologics that target particular molecules involved in the pathogenic process. Preliminary investigations and clinical trials have demonstrated the efficacy of biologics and provided additional insights for the era of refractory or corticosteroid-dependent EGE biologics.

Monteverdia ilicifolia: um protetor gástrico / Monteverdia ilicifolia: a gastric protector / Monteverdia ilicifolia: protector gástrico

Monteverdia ilicifolia, conhecida popularmente como espinheira-santa, é uma planta da família Celastraceae de relevante ação terapêutica devido às suas propriedades medicinais, principalmente a sua atividade gastroprotetora, possuindo efeitos comprovados sobre acidez e úlceras estomacais. Desta forma o objetivo deste trabalho foi encontrar na literatura evidências para o uso terapêutico da M. ilicifolia, como uma alternativa frente aos fármacos sintéticos disponíveis na indústria farmacêutica voltados para o tratamento de problemas estomacais. Foi utilizado no presente trabalho a base de dados Google acadêmico. Os distúrbios estomacais afetam milhares de pessoas, influenciando de forma negativa na qualidade de vida da população e gerando prejuízos ao sistema de saúde. Os fármacos com atividade sobre a secreção da acidez gástrica são as medicações mais prescritas para essas enfermidades, destacando-se os antagonistas do receptor H2 de histamina e os inibidores da bomba de prótons, amplamente utilizados para o tratamento de úlceras e gastrite. Com o tempo, esses medicamentos passaram a ser indiscriminadamente utilizados, prática que põem em risco a saúde íntegra dos pacientes, mediante aos diversos efeitos adversos que esses medicamentos podem causar. As plantas medicinais têm sido aplicadas na terapia de diversas doenças em toda a história da humanidade. Nesse contexto, a espinheira-santa surge como uma alternativa segura e eficaz para a prevenção e tratamento dessas patologias. Dentre os compostos bioativos que podem desempenhar a atividade gastroprotetora, destacam-se os taninos, triterpenos e flavonóides. Os estudos analisados demonstram que a M. ilicifolia possui relevante ação terapêutica, com potencial para substituir os fármacos usualmente empregados no tratamento de úlceras e gastrite.

The Monteverdia ilicifolia, popularly known as espinheira-santa, is a plant of the Celastraceae's family with relevant therapeutic action due to its medicinal properties, mainly its gastroprotective activity, and possesses proven effects on acidity and stomach ulcers. The aim of this work was to find in the literature evidence for the therapeutic use of M. ilicifolia, as an alternative to the synthetic drugs available in the pharmaceutical industry for the treatment of stomach problems. The academic Google database was used in this work. Stomach disorders affect thousands of people, negatively influencing the population's quality of life and causing damage to the health system. The drugs with activity on gastric acid secretion are the most prescribed medications for these diseases, especially histamine H2 receptor antagonists and proton pump inhibitors, widely used for the treatment of ulcers and gastritis. Over time, these drugs began to be used indiscriminately, a practice that jeopardizes the health of patients, due to the various adverse effects that these drugs can cause. Medicinal plants have been applied in the therapy of various diseases throughout human history. In this context, the espinheira-santa emerges as a safe and effective alternative for the prevention and treatment of these pathologies. Among the bioactive compounds that can perform a gastroprotective activity, tannins, triterpenes, and flavonoids stand out. The analyzed studies demonstrate that M. ilicifolia has relevant therapeutic action, with the potential to replace the drugs usually used in the treatment of ulcers and gastritis.

Monteverdia ilicifolia, conocida popularmente como espinheira-santa, es una planta de la familia Celastraceae de relevante acción terapéutica por sus propiedades medicinales, principalmente su actividad gastroprotectora, con efectos probados sobre la acidez y las úlceras estomacales. Así, el objetivo de este trabajo fue encontrar evidencia en la literatura para el uso terapéutico de M. ilicifolia, como alternativa a las drogas sintéticas disponibles en la industria farmacéutica destinadas al tratamiento de problemas estomacales. En este trabajo se utilizó la base de datos académica de Google. Los trastornos estomacales afectan a miles de personas, influyendo negativamente en la calidad de vida de la población y provocando daños en el sistema de salud. Los fármacos con actividad sobre la secreción ácida gástrica son los más prescritos para estas enfermedades, especialmente los antagonistas de los receptores H2 de histamina y los inhibidores de la bomba de protones, muy utilizados para el tratamiento de úlceras y gastritis. Con el tiempo, estos medicamentos comenzaron a utilizarse de forma indiscriminada, práctica que pone en riesgo la salud de los pacientes, debido a los diversos efectos adversos que estos fármacos pueden ocasionar. Las plantas medicinales se han aplicado en la terapia de diversas enfermedades a lo largo de la historia humana. En este contexto, la espinheira-santa surge como una alternativa segura y eficaz para la prevención y el tratamiento de estas patologías. Entre los compuestos bioactivos que pueden realizar actividad gastroprotectora destacan los taninos, los triterpenos y los flavonoides. Los estudios analizados demuestran que M. ilicifolia tiene una acción terapéutica relevante, con potencial para reemplazar los fármacos habitualmente utilizados en el tratamiento de úlceras y gastritis.

Protective effect of total triterpenoids from Chaenomeles speciosa against Helicobacter pylori-induced gastritis in mice / 中国中药杂志

This study investigated the protective effect of total triterpenoids from Chaenomeles speciosa against Helicobacter pylori(Hp)-induced gastritis in mice and explored its possible mechanism. The chronic atrophic gastritis(CAG) model mice were randomly divided into four groups of model, total triterpenoids from C. speciosa(50 and 100 mg·kg~(-1)) and triple therapy, with C57 BL/6 J mice without Hp infection taken as the normal group. Mice in the treatment groups were given corresponding drugs once a day for 4 weeks. Then the following indexes were detected: the contents of reactive oxygen species(ROS), monocyte chemotactic protein 1(MCP-1), keratinocyte chemokines(KC), TNF-α, IL-1β, IL-6, IL-18, IL-4 and IL-10 in blood and gastric tissue, the activities and contents of LDH, MPO, SOD, GSH-Px, CAT and MDA in gastric tissue and the activities of β-glucuronidase, β-galactosidase, cathepsins B and D in blood, gastric tissue and lysosome. Besides, the mRNA expression levels of Toll-like receptor 4(TLR4), myeloid differentiation factor 88(MyD88), Bcl-2, Bcl-xl, Bax and Bad in gastric tissue were determined by quantitative real-time PCR. Western blot was employed to detect the protein expression levels of TLR4, MyD88, p-IKKβ, p-IκBα, NOD-like receptor 3(NLRP3), apoptosis-associated speck-like protein(ASC), pro-caspase-1, caspase-1, thioredoxin-interacting protein(TXNIP), pro-IL-1β, pro-IL-18, Bcl-2, Bcl-xl, Bax, Bad, cytochrome C, apoptotic protease-activating factor-1(Apaf-1), pro-caspase-9, pro-caspase-3, cleaved-caspase-9, cleaved-caspase-3, poly(ADP-ribose) polymerase 1(PARP-1), cleaved-PARP-1 and cytosol and nucleus NF-κB p65 in gastric tissue. The results indicated that the total triterpenoids from C. speciosa significantly suppressed Hp proliferation, alleviated the damage to gastric mucosa and improved lymphocyte infiltration and gland atrophy. They were also effective in reducing the activities of β-glucuronidase, β-galactosidase, cathepsins B and D in blood and gastric tissue, elevating the activities of β-glucuronidase and cathepsin D in lysosomal organelles, decreasing the contents of ROS, MCP-1, KC, TNF-α, IL-1β, IL-6, IL-18 in blood, MDA content and MPO and LDH activities in gastric tissue and increasing the contents of IL-4 and IL-10 in blood and activities of SOD, CAT and GSH-Px in gastric tissue. Other phenomena were also observed after the treatment with total triterpenoids from C. speciosa, including the down-regulation of the mRNA and protein expression levels of TLR4, MyD88, Bax and Bad, the protein expression levels of p-IKKβ, p-IκBα, NLRP3, ASC, pro-caspase-1, caspase-1, TXNIP, pro-IL-1β, pro-IL-18, cytochrome C, Apaf-1, cleaved-caspase-9, cleaved-caspase-3, cleaved-PARP-1 and nuclear NF-κB p65, reduction of p-IKKβ/IKKβ and p-IκBα/IκBα ratios and up-regulation of the mRNA and protein expression levels of Bcl-2 and Bcl-xl, up-regulation of pro-caspase-9, pro-caspace-3, cytosol NF-κB p65 protein expression levels and Bcl-2/Bax and Bcl-xl/Bad ratios in gastric tissue. These aforementioned results suggest that the total triterpenoids from C. speciosa have significant protective effects against CAG induced by Hp, and its mechanism may be related to enhancing the function of endogenous antioxidant system, suppressing the oxidative stress and inflammatory reaction induced by Hp, correcting lysosomal dysfunction and inflammatory activation of TLR4/NF-κB/NLRP3 inflammasome signaling pathway and thus inhibiting mitochondria-mediated apoptosis.

Infección por Helicobacter pylori: Frecuencia del fracaso del tratamiento de primera línea / Helicobacter pylori infection. Frequency of first-line treatment failure

La resistencia bacteriana a ciertos antibióticos condiciona el éxito del tratamiento erradicador de la infección gástrica por Helicobacter pylori y es motivo de creciente preocupación a nivel mundial. Dada la escasa evidencia publicada en Argentina sobre este tema, nuestro objetivo fue investigar factores asociados a la persistencia de H. pylori post-tratamiento antibiótico. Se determinó la frecuencia de fracaso terapéutico en 81 pacientes con gastritis por H. pylori tratados en nuestro Servicio y sometidos al estudio de urea en aire espirado para confirmar la erradicación de la infección. La edad promedio fue 58±12 y 43.2% eran hombres. La frecuencia de fracaso terapéutico fue 17.3%. De los dos esquemas más utilizados, la frecuencia de fracaso fue mayor con claritromicina + amoxicilina que con levofloxacina + amoxicilina (25% vs. 6.6%, p=0.04). Como factores de riesgo investigamos las siguientes variables: edad, género, síntomas, tabaquismo, consumo de anti-inflamatorios, diabetes, obesidad, tipo y duración de tratamiento. En el análisis univariado, el uso de esquemas con claritromicina y el género masculino se asociaron significativamente a persistencia de la infección [OR 4.2 (1.1-15.6) y 5.2 (1.1-26.4)]. En el análisis multivariado, el uso de esquema con claritromicina permaneció asociado al fracaso terapéutico [OR 5.38 (1.1-29.5)]. Concluimos que la inclusión de claritromicina en el esquema terapéutico para la gastritis por H. pylori se asoció a mayor fracaso terapéutico. Este fracaso es atribuible a alta prevalencia de resistencia de H. pylori a ese antibiótico en la población atendida en nuestro hospital y cuestiona las prácticas habituales de tratamiento en nuestro medio.

Antibiotic resistance may hinder the efficacy of eradication therapy against Helicobacter pylori infection and it has become a major concern worldwide. Due to the relatively scarce evidence published in Argentina on this topic, our aim was to describe factors associated with H. pylori persistence after antibiotic treatment. The therapeutic failure rate was described among 81 patients with H. pylori gastritis treated in our Hospital with a post-treatment urea breath test to determine successful eradication. Mean age was 58 ± 12 and 43.2% were male subjects. H. pylori persistence was observed in 17.3% of subjects. Therapeutic failure was more common among patients receiving clarithromycin + amoxicillin therapy that among those receiving levofloxacin + amoxicillin (25% vs. 6.6%, p = 0.04). The following variables were assessed: age, gender, referral symptoms, smoking, anti-inflammatory use, diabetes, obesity, treatment type and duration. Clarithromycin-based therapy and male gender were associated with infection persistence on univariate analysis [OR 4.2 (1.1-15.6) and 5.2 (1.1-26.4)]. On multivariate analysis, clarithromycin-based was associated with infection persistence [5.38 (1.1-29.5)]. We conclude that clarithromycin-based therapy is significantly associated with treatment failure. This failure may be due to an elevated prevalence of H. pylori resistance to clarithromycin in the population under study and raises the question on the utility of such therapeutic alternative.

Anti-Helicobacter pylori and Anti-inflammatory Properties of Eugenia uniflora L

Abstract Helicobacter pylori is a bacterium that reaches half of the world population and it's recognized as the main cause of chronic gastritis and peptic ulcer. In this study, we evaluated the anti-H. pylori, antioxidant and immunomodulatory activities of the methanolic (MeOH) extract of Eugenia uniflora leaves and chemical profile. Anti-H. pylori activity was evaluated by spectrophotometric broth microdilution technique by determining the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC), in addition to the evaluation of the effect on the urease enzyme. The antioxidant activity was evaluated by capturing O2 •-, HOCl e NO• radicals. The immunomodulatory effect was evaluated on the cytokines TNF-α, IL-6 and on nitric oxide through inhibition in LPS-stimulated macrophages. The chemical profile was performed by total phenolic, tannin and flavonoid contents and mass spectrometry analysis by ESI-FT-ICR MS. In the anti-H. pylori assay the extract showed MIC of 128 μg/mL, however it did not obtain MBC. The extract also showed ability to inhibit the urease enzyme about 20%. The antioxidant activity of the MeOH extract showed EC50 values of 29.77 µg/mL, 15.71 µg/mL and 442.10 µg/mL to O2 •-, HOCl and NO•, respectively. The extract also showed influence on the release of TNF-α, IL-6 and NO in LPS-stimulated macrophages, ranging from 39% to 97% inhibition. Flavonoids, phenylpropanoids, tannins, triterpenoids and carbohydrates were the major classes of compounds present in the MeOH extract as identified by (-)-ESI-FT-ICR MS. The results indicate important anti-H. pylori, antioxidant and immunomodulatory activities from Eugenia uniflora highlighting its importance in the prevention and treatment of diseases caused by H. pylori infection.

Role of rebamipide and or pantoprazole in preventing dexamethasone induced gastritis in senile male albino rats

Aim of the work: gastritis is the inflammation of the lining of the stomach .It is caused by many factors like infection by Helicobacter pylori, drug induced such as aspirin, Non-Steroidal Anti-Inflammatory Drugs [NSAIDs], corticosteroids and alcohol consumption. Pantoprazole prevents HCL formation by blocking proton pumps in parietal cells of the stomach leading to stoppage of pepsinogen enzyme activation

Rebamipide stimulates prostaglandins synthesis so the mucous barrier can be build up to protect the gastric mucosa, so this study aimed to evaluate the efficacy of Pantoprazole and Rebamipide on stomach mucosa protection from the gastritis that was induced by Dexamethasone in rats

Material and methods: twenty-five male senile albino rats were included in this study and divided into five groups: Gl [Control group], G2 [Dexamethasone administrated group], G3 [Pantoprazole administrated group], G4 [Rebamipide administrated group] and G5 [Pantoprazole and Rebamipide administrated group]

The collected stomach specimens were subjected to hematoxylin and eosin, PAS and alcian blue stains

Results: the most weight loss was detected in Dexamethasone administrated group, while the least weight loss was realized in dexamethasone and Rebamipide administrated group. Gastric samples showed improvement in gastric mucosa in G3 and G4, but the best improvement was demonstrated in G3

Conclusion: Rebamipide has a better protective effect than the Pantoprazole in prevention of gastric mucosal injuries

Eosinophilic Gastroenteritis Presenting as Small Bowel Obstruction.

Eosinophilic gastroenteritis is a rare disease of unknown etiology characterized by eosinophilic infiltration of bowel wall to a variable depth. A 38 year old female presented with loose stool and vomiting since 3 days. She gave history of pain abdomen and weight loss since six months. Barium study revealed ascending colon stricture just proximal to the hepatic flexure ? malignant. A colonic biopsy was done, which was reported as edematous colonic mucosa with mild increase in eosinophils. Intra-operatively, a dense long segment stricture was found in the ascending colon extending to the caecum which warranted a right hemicolectomy. Histopathology revealed dense infiltration of eosinophils in the entire thickness of ileal and caecal wall. The diagnosis of eosinophilic gastroenteritis was made. Patient responded well to steroids. The case is being reported to highlight its rarity due to caecal involvement, presentation as intestinal obstruction and missed diagnosis on endoscopic biopsy.

Effect of Helicobacter pylori on the mucosa of the lower end of the esophagus in induced chronic gastritis in adult albino rats: a histological and immunohistochemical study

Although Helicobacter pylori is linked to the occurrence of chronic gastritis, its effect on the lower end of the esophagus is still an open question. This study aimed to investigate the histological changes in the mucosa in the lower end of the esophagus after experimental induction of chronic gastritis by H. pylori, with special emphasis on changes occurring under its different lines of eradication. Thirty-six adult female albino rats were divided into control [group I] and experimental [group II] groups. The latter group received 0.5 ml of H. pylori brucella broth through an orogastric tube in daily morning doses for 1 week. Eight weeks later, rats of group II were further subdivided into four subgroups: lla, lib, He, and lid. Rats of the latter three subgroups were treated for an additional 4 weeks with amoxicillin, curcuminoid extract, and a mixture of both, respectively, whereas subgroup lla underwent no treatment for H. pylori. Twelve weeks after induction of H. pylori, samples from the lower end of the esophagus were stained with H and E, Mallory's trichrome, and nitrotyrosine immunoperoxidase and studied morphometrically. Subgroup lla showed an increase in the height of the epithelium that had inflammatory infiltrations, mitotic cells, spaces separating prickle cells, and many keratohyalin granules. The lamina propria showed elongated connective tissue papillae, wide spaces, and inflammatory cells. There was a highly significant increase in the mean number of inflammatory cells, epithelial and connective tissue papillae height, thickness of keratohyalin granules-containing layer, and area% of nitrotyrosine immunostaining. Subgroup lib treated with amoxicillin showed worsening of histological and immunohistochemical changes as well as of all morphometrically measured values. However, subgroups He and lid showed improvement in most of these changes, H. pylori treated with amoxicillin worsened the inflammatory changes, whereas curcuminoid extract improved the condition. Further studies to evaluate the use of curcumin with other anti H. pylori drugs are needed

Helicobacter pylori eradication does not influence gastroesophageal reflux disease: a prospective, parallel, randomized, open-label, controlled trial / Erradicação do Helicobacter pylori não influencia a doença do refluxo gastroesofágico: estudo prospectivo, paralelo, randomizado, aberto e controlado

CONTEXT: Helicobacter pylori has been associated with worsening of gastroesophageal reflux disease (GERD). OBJECTIVE: To evaluate the effect of H. pylori eradication in GERD patients. METHODS: We conducted a prospective, randomized, controlled trial performing symptom evaluation, endoscopy, histology, manometry and esophageal pH testing on GERD patients. Patients infected with H. pylori were randomized to: 1) eradication treatment plus proton pump inhibitors treatment, or 2) proton pump inhibitors alone. Patients not infected constituted a negative control group. After 3 months, patients were re-evaluated by symptom assessment, endoscopy, histology and manometry. RESULTS: GERD treatment resulted in significantly higher lower esophageal sphincter pressure, as measured by mean expiratory pressure, in H. pylori negative patients. There was significantly lower proportion of hypotensive waves and significantly higher proportion of normotensive waves in non-eradicated patients. All symptom scores were significantly reduced in the post-treatment period compared to baseline, to values that were similar among the three groups, in the post-treatment period. In the post-treatment period, erosive esophagitis was significantly less frequent on those not eradicated. CONCLUSION: Manometric, clinical and endoscopic data showed no benefit in eradicating H. pylori in GERD. Our data supports the hypothesis that H. pylori eradication does not influence GERD.

CONTEXTO: Existem trabalhos associando a erradicação do Helicobacter pylori à piora da doença do refluxo gastroesofágico (DRGE). OBJETIVO: Avaliar o efeito da erradicação do H. pylori em pacientes com DRGE. MÉTODOS: Estudo prospectivo, randomizado, controlado em que se avaliaram clínica, endoscopia digestiva alta, histologia, manometria e pHmetria de pacientes com DRGE. Pacientes infectados pelo H. pylori foram randomizados para: 1) erradicação da infecção seguida de tratamento com inibidor de bomba protônica, ou 2) tratamento com inibidor de bomba protônica apenas. Os não-infectados constituíram grupo-controle negativo. Após 3 meses, os pacientes foram reavaliados. RESULTADOS: A pressão do esfíncter inferior do esôfago, medida pela pressão expiratória máxima, foi significativamente maior em pacientes H. pylori negativos. Houve redução significativa na proporção de ondas hipotensivas e aumento significativo na proporção de ondas normotensivas nos pacientes que permaneceram Helicobacter pylori positivos. Todos os escores de sintomas foram reduzidos significativamente em comparação ao período inicial, para valores semelhantes, entre os três grupos, no pós-tratamento. Esofagite erosiva foi significativamente menos frequente no período pós-tratamento no grupo não-erradicado. CONCLUSÃO: Os achados manométricos, clínicos e endoscópicos não mostram benefício em se erradicar a infecção em pacientes com DRGE. Este estudo apoia a hipótese de que a erradicação do H. pylori não influencia a DRGE.

Successful Treatment of Eosinophilic Gastroenteritis with Clarithromycin

Eosinophilic gastroenteritis (EGE) is an uncommon disease characterized by eosinophilic infiltration of the gastrointestinal tract, which is usually associated with abdominal pain, diarrhea, ascites, and peripheral eosinophilia. Steroids remain the mainstay of treatment for EGE, but symptoms often recur when the dose is reduced. Macrolides have immunomodulatory effects as well as antibacterial effects. The immunomodulatory effect results in inhibition of T-lymphocyte proliferation and triggering of T-lymphocyte and eosinophil apoptosis. Macrolides also have a steroid-sparing effect through their influence on steroid metabolism. We report a rare case of EGE, which relapsed on steroid reduction but improved following clarithromycin treatment.

Gastritis colágena: presentación de un caso clínico y revisión de la literatura / Collagenous gastritis: presentation of a clinical case and review of the literature

Collagenous gastritis (CG) is an exceptional disease characterized by the deposition of subepithelial collagen band thicker than 10 tm in association with increased inflammatory cell infiltrate of the lamina propria. These histological features seem to overlap with other "collagenous enterocolitides". The pathogenesis and prognosis of CG still remains unclear. CG presentation is seen completely different in two major subsets of patients, children and adults. We report a 38 year-old man with abdominal pain and chronic diarrhea. The upper endoscopy showed a severe gastritis with biopsies that revealed CG, and the colonoscopy was normal with biopsies indicative of collagenous colitis. This characteristic form of clinical presentation in adult patients suggests that subepithelial collagen deposition may be a generalized disease affecting different areas of the gastrointestinal tract. The patient was treated with proton-pump-inhibitors and budesonide, with clinical improvement.

La gastritis colágena (GC) es una enfermedad poco frecuente caracterizada por el depósito subepitelial de colágeno de grosor mayor de 10 um asociado a infiltrado inflamatorio en la lámina propia. Estos hallazgos histológicos son similares a los encontrados en la enterocolitis colágena. La patogénesis y pronóstico de la GC permanece aún desconocida. La presentación clínica de la GC se observa de manera diferente en dos subgrupos de pacientes, niños y adultos. Se presenta el caso de un hombre de 38 años con dolor abdominal y diarrea crónica. La endoscopia digestiva alta mostró una gastritis severa con biopsias que revelaron la presencia de GC y la colonoscopia fue normal con biopsias que mostraron una colitis colágena. Esta forma de presentación clínica en el paciente adulto sugiere que el depósito de colágena subepitelial corresponde a una enfermedad generalizada que puede afectar a diferentes áreas del tracto gastrointestinal. El paciente fue tratado con inhibidores de la bomba de protones y budesonida con mejoría clínica.

Gastroenterite eosinofílica em criança, levando à desnutrição / Eosinophilic gastroenteritis and children with malnutrition

A gastroenterite eosinofílica é uma afecção caracterizada pela infiltração maciça de eosinófilos no trato gastrointestinal. Foi descrita pela primeira vez por Kaijser em 1937 e pode acometer qualquer área do trato gastrointestinal. A causa e o mecanismo de infiltração de eosinófilos são ainda desconhecidos. A apresentação pode variar, dependendo da localização, assim como da profundidade e da extensão do acometimento, e geralmente tem curso crônico. É uma doença relativamente rara, que afeta predominantemente adultos jovens do sexo masculino. (AU)

Eosinophilic gastroenteritis is a condition with extensive infiltration of eosinophils in the gastrointestinal tract. It was first described by Kaijser en 1937 and can affect any part of gastrointestinal tract. The cause and the real way for infiltration are unknown. Presentation may vary depending on location as well as depth and extent of bowel wall involvement and usually runs a chronic relapsing course. It is a rare disease that affects mainly young adult men. (AU)

Gastritis flegmonosa: caso clínico y revisión de la literatura / Phlegmonous gastritis: case report and review of the literature

Phlegmonous gastritis in an infrequent condition with high mortality characterized by suppurative infection of the gastric wall as a consecuence of a localized or hematogenous infection. The clinical and laboratory findings are nonsoecific and the endoscopy and endosonography are the methods of choice for the diagnosis. The treatment should by prompt and sometimes requires antibiotic therapy in association with gastric resection. In this report we present a case of phlegmonous gastritis as a complication of an endoscopic procedure.

Suggestive parameters for eradication therapy in children with Helicobacter pylori gastritis.

The relationship between Helicobacter pylori (H. pylori) infection and recurrent abdominal pain in children is still controversial. H. pylori-infected children with recurrent abdominal pain generally do not require treatment. However, benefit of treatment has been known to produce dramatic improvements in some patients. Furthermore, H. pylori-infected is associated with growth retardation, iron deficiency anemia and thrombocytopenia. The objective of this study was to find suggestive parameters for eradication of H. pylori gastritis. From 1992 to 2004, medical records of 42 children diagnosed as having H. pylori infection by endoscopy were retrospectively reviewed. Of those 42 patients, there were 36 patients with H. pylori gastritis without gastric or duodenal ulcer (85.7%), and 6 patients with ulcers (14.3%). Children with H. pylori gastritis were divided into 2 groups: responsive and unresponsive. Data including the duration of abdominal pain, endoscopic finding, histology, treatment, outcome and final diagnosis were collected. Additional data were obtained by telephone and letters. Of 36 patients, there were 24 and 12 patients in responsive and unresponsive groups, respectively. Three patients with anemia were all presented in the responsive group. Those experiencing abdominal pain less than 3 months more commonly belonged to the responsive group (P = 0.21). Marked erythema of gastric mucosa was only seen in the responsive group (P = 0.136). All cases of chronic moderate-active gastritis appeared in the responsive group (p = 0.03). In conclusion, iron deficiency anemia and chronic moderate-active gastritis should be the suggestive parameters for eradication therapy in children with H. pylori gastritis.

Efeito da administração de vitamina C sobre a colonização do estômago por Helicobacter pylori / Effect of vitamin C administration on gastric colonization by Helicobacter pylori

RACIONAL: O tratamento convencional de Helicobacter pylori consiste na utilização de antimicrobianos, aos quais uma minoria expressiva de pacientes não responde. Tratamentos alternativos para a infecção têm sido propostos, incluindo o uso de antioxidantes. Destaque crescente tem sido atribuído à vitamina C ao se demonstrar que concentrações da mesma no estômago de indivíduos infectados com H. pylori são substancialmente menores do que as de indivíduos saudáveis. Doses farmacológicas de vitamina C foram investigadas na erradicação de H. pylori com resultados controversos. OBJETIVO: Avaliar o efeito da administração via oral de vitamina C sobre a colonização de estômago por H. pylori em pacientes infectados, com gastrite crônica ou com úlcera péptica cujos tratamentos convencionais não resultaram em erradicação. MATERIAL E MÉTODOS: Protocolo I: estudo aleatório, duplo-cego, controlado por placebo em pacientes com gastrite crônica, sem tratamento prévio para a infecção. Protocolo II: estudo aberto, não controlado em pacientes com úlcera péptica e pelo menos dois tratamentos prévios de erradicação. O tratamento consistiu em vitamina C 5 g/dia durante 28 dias consecutivos. Seu efeito foi avaliado pelo teste respiratório com 14C-uréia quanto à taxa de erradicação, à variação de radioatividade e à supressão da infecção. RESULTADOS: No protocolo I, 38 pacientes completaram o estudo, 21 recebendo vitamina C e 17 recebendo placebo durante 28 dias. A taxa de erradicação "por protocolo" com vitamina C foi zero, intervalo de confiança de 95 por cento: 0 por cento-15 por cento. No protocolo II, oito pacientes completaram o tratamento. A taxa de erradicação foi zero, com intervalo de confiança de 95 por cento: 05-32 por cento. Não houve diminuição da carga bacteriana. CONCLUSÕES: A administração de vitamina C na dosagem diária de 5 g durante 28 dias não é eficaz na erradicação de infecção por H. pylori, nem altera quantitativamente sua carga no estômago dos pacientes infectados.

The Changes of Ammonia and Epidermal Growth Factor Concentration in Gastric Juice before and after the Helicobacter pylori Eradication / 대한소화기학회지

BACKGROUND/AIMS: Helicobacter pylori (H. pylori) infection is the cause of peptic ulcer diseases, and gastric cancer. Hydrolysis of urea generating ammonia may cause cytotoxic effects on the gastric epithelium. The ammonia may induce the synthesis of epidermal growth factor (EGF) in gastric epithelium as an adaptive cytoprotective mechanism. The first aim was to examine the concentration of ammonia and EGF in gastric juice before and after H. pylori eradication in functional dyspepsia patients. The second aim was to examine the correlation among ammonia concentration, EGF concentration, and inflammatory score of gastritis. METHODS: The concentration of ammonia and EGF were measured by ELISA. The grade and severity of gastritis were measured according to the updated Sydney system. RESULTS: The concentration of ammonia in gastric juice was much higher in the H. pylori positive subjects (10,787 +/- 6,584 micro mol/L) than in the negative subjects (2,339 +/- 1,158 micro mol/L, p<0.0001). The concentrations of EGF in gastric juice was much higher in the positive subjects (1,462 +/- 393 pg/mL) than in the negative subjects (1,088 +/- 499 pg/mL, p<0.005). The concentration of ammonia and EGF in gastric juice showed significant correlation (r=0.63, p<0.0001). The concentrations of ammonia and histologic severities showed significant correlation (r=0.41, p<0.0001). Moreover, the level of EGF in gastric juice and histologic severities showed positive correlation (r=0.20, p<0.005). CONCLUSIONS: As the concentration of ammonia in gastric juices increased, the concentration of EGF was also increased in functional dyspepsia with H. pylori infection. The concentration of EGF in gastric juice may play a role in the adaptive cytoprotection in H. pylori- induced gastritis.

The Changes of Matrix Metalloproteinase-9 Expression in the Gastric Antral Mucosa after Helicobacter pylori Eradication: Immunohistochemical Study / 대한소화기학회지

BACKGROUND/AIMS: In this study, we analysed the changes of matrix metalloproteinase-9 (MMP-9) expression in the gastric antral epithelium in respect to H. pylori eradication. METHODS: Twenty patients with H. pylori-positive chronic gastritis or peptic ulcer were studied. The expression of MMP-9 in the gastric antral biopsy specimens were compared before and after H. pylori eradication using immunohistochemical study. The positive rates and intensity of MMP-9 staining were evaluated at surface mucous cells and pyloric gland cells. RESULTS: The positive rate of MMP-9 staining in antral mucosal epithelial cells of H. pylori chronic gastritis is 63.8%. The positive rates of MMP-9 staining in the surface mucous cells and pyloric gland cells were 75.5% and 52.0% before H. pylori eradication, respectively. On the contrary, the rates were 85.5% and 82.0% after eradication. The MMP-9 overexpression in the pyloric gland cells were noticeably increased after H. pylori eradication. Strong positive staining of MMP-9 was increased significantly after H. pylori eradication in the pyloric gland cells. CONCLUSIONS: These results suggest that MMP-9 over-expression is associated with H. pylori infection as a host inflammatory response. The increased expression after H. pylori eradication indicates that MMP-9 may have a important role in remodeling or early tissue repairing process of gastric mucosa.

Ursodeoxycholic acid does not interfere with in vivo Helicobacter pylori colonization

A low frequency of Helicobacter pylori in the gastric mucosa of patients with alkaline gastritis has been reported. At the same time, it can be noted that the growth of bacteria can be inhibited by bile acids. We studied 40 patients with chronic gastritis related to Helicobacter pylori in order to determine the effect of ursodeoxycholic acid on this infection. Diagnoses of the infection and the inflammatory process were obtained by histologic study of gastric biopsies collected during endoscopy. Two groups were studied: group I received ursodeoxycholic acid - 300 mg/day, and group II received the placebo, twice a day, both for 28 days. The colonization by Helicobacter pylori and the intensity of the mononuclear and polymorphonuclear inflammatory infiltrate were determined before (time 1) and after (time 2) treatment. Ursodeoxycholic acid had no effect on the Helicobacter pylori infection. A significant reduction in the intensity of the mononuclear inflammatory infiltrate of the gastric antrum mucosa was observed in patients from group I, when we compared not only times 1 and 2 but also groups I and II. However, this was not the case with the body mucosa. We concluded that ursodeoxycholic acid had no action on the colonization by Helicobacter pylori or on the polymorphonuclear inflammatory infiltrate, but it caused a significant reduction in the intensity of the mononuclear inflammatory infiltrate of the gastric antrum